Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
Cholangiocarcinoma
Recently published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), VHIO investigators have established…
Cholangiocarcinoma (CCA) is a highly aggressive, heterogeneous disease that currently accounts for 15% of all liver cancers and approximately 3%…
